secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2026-08-06T20:18:50+00:00
Accession:  0001641489-26-000029
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q2 net loss $13.1M; Phase 3 T1D trial enrollment to complete Q3 2026
--------------------------------------------------------------------------------

- Net loss of $13.1M ($1.05 per share) vs $6.0M loss ($0.92) in Q2 2025; R&D spend rose to $8.8M from $4.1M.
- Cash and equivalents $86.6M at June 30, 2026; company expects runway through CATT1 topline data readout.
- Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes expected to complete enrollment in Q3 2026.
- Phase 2a Hybrid CATT1 trial (hybrid closed-loop) to initiate before year-end 2026; KOL event planned Q4 2026.
- Six-month revenue of $36.8M (vs $0 in prior year) from a milestone; net income of $11.1M for H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148926000029/0001641489-26-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148926000029/vtvt-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001641489-26-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer